Recent progress and challenges in the discovery of new neuraminidase inhibitors

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 4, 2013, Pages 409-423

  Chamni, Supakarn ^a   De Eknamkul, Wanchai ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Chemical synthesis; Enzyme based inhibition assay; Flavonoids; Influenza virus neuraminidase; Neuraminidase inhibitor

Indexed keywords

ABT 675; AMANTADINE; AROMATIC COMPOUND; AURONE DERIVATIVE; BENZOIC ACID DERIVATIVE; BIFLAVONOID DERIVATIVE; BIOCHANIN A; CALYCOSIN; CATECHIN; CHALCONE DERIVATIVE; DAIDZEIN; FLAVAN DERIVATIVE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOLE DERIVATIVE; GENISTEIN; HETEROCYCLIC COMPOUND; HYDROXYFLAVANONE DERIVATIVE; INFLUENZA VACCINE; ISOFLAVONE DERIVATIVE; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; PHENYLBENZOPYRANE DERIVATIVE; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

CONFORMATIONAL TRANSITION; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; REVIEW; SEASONAL INFLUENZA; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; COMPUTER-AIDED DESIGN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875190123     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.765861     Document Type: Review

References (104)

1. Chand P. Recent advances in the discovery and synthesis of neuraminidase inhibitors. Expert Opin Ther Patents 2005;15:1009-25
2. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007 - 08 season. Emerg Infect Dis 2009;15:552-60
3. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-15
4. Schunemann HJ, Hill SR, Kakad M, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007;7:21-31
5. Earhart KC, Elsayed NM, Saad MD, et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Health 2009;2:74-80
6. de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72
7. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005;437:1108
8. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009;459:931-9
9. Das K, Aramini JM, Ma LC, et al. Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol 2010;17:530-8
10. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 2007;6:967-74
11. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73
12. Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antiviral Res 2006;71:372-8
13. Grienke U, Schmidtke M, von Grafenstein S, et al. Influenza neuraminidase: a druggable target for natural products. Nat Prod Rep 2012;29:11-36
14. Chand P, Kotian PL, Dehghani A, et al. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent anti-influenza activity. J Med Chem 2001;44:4379-92
15. Grienke U, Schmidtke M, Kirchmair J, et al. Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from alpinia katsumadai. J Med Chem 2009;53:778-86
16. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005;49:4515-20
17. Kongkamnerd J, Cappelletti L, Prandi A, et al. Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. Bioorg Med Chem 2012;20:2152-7
18. Kongkamnerd J, Milani A, Cattoli G, et al. The quenching effect of flavonoids on 4-methylumbelliferone, a potential pitfall in fluorimetric neuraminidase inhibition assays. J Biomol Screen 2011;16:755-64
19. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 2002;12:159-66
20. Oxford JS. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology. Rev Med Virol 2000;10:119-33
21. Rao A, Somayajulu D. Influenza classification from nucleotide sequence database. J Comput Sci Syst Biol 2011;4:77-80
22. Air GM. Influenza neuraminidase. Influenza Other Respi Viruses 2012;6:245-56
23. Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 2011;11:134
24. Xie Y, Gong J, Li M, et al. The medicinal potential of influenza virus surface proteins: hemagglutinin and neuraminidase. Curr Med Chem 2011;18:1050-66
25. von Itzstein M, Thomson R. Anti-influenza drugs: the development of sialidase inhibitors. Handb Exp Pharmacol 2009;189:111-54
26. Gong J, Xu W. Different synthetic strategies of oseltamivir phosphate: a potent influenza neuraminidase inhibitor. Curr Med Chem 2008;15:3145-59
27. Liu Y, Zhang J, Xu W. Recent progress in rational drug design of neuraminidase inhibitors. Curr Med Chem 2007;14:2872-91
28. Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007;13:3531-42
29. Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007;79:1577-86
30. Gong J, Xu W, Zhang J. Structure and functions of influenza virus neuraminidase. Curr Med Chem 2007;14:113-22
31. Johnson DS, Li JJ. In the art of drug synthesis. John Wiley and Sons; New Jersey: 2007
32. Roberts NA, Govorkova EA. The activity of neuraminidase inhibitor oseltamivir against all subtypes of influenza viruses. In: Mitrasinovic PM, editor, Global view of the fight against influenza. Nova Science, New York; 2009
33. Mihajlovic ML, Mitrasinovic PM. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Biophys Chem 2008;136:152-8
34. Mihajlovic ML, Mitrasinovic PM. Some novel insights into the binding of oseltamivir and zanamivir to H5N1 and N9 influenza virus neuraminidases: a homology modeling and flexible docking study. J Serb Chem Soc 2009;74:1-13
35. Mihajlovic ML, Mitrasinovic PM. Applications of the ArgusLab4/AScore protocol in the structure-based binding affinity prediction of various inhibitors of group-1 and group-2 influenza virus neuraminidases (NAs). Mol Simul 2009;35:311-24
36. Govorkova EA, Leneva IA, Goloubeva OG, et al. Comparison of efficacies of rwj-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001;45:2723-32
37. Mitrasinovic PM. Advances in the structure-based design of the influenza a neuraminidase inhibitors. Curr Drug Targets 2010;11:315-26
38. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006;443:45-9
39. Amaro RE, Cheng X, Ivanov I, et al. Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations. J Am Chem Soc 2009;131:4702-9
40. Amaro RE, Swift RV, Votapka L, et al. Mechanism of 150-cavity formation in influenza neuraminidase. Nat Commun 2011;2:388
41. Hussain Basha S, Prasad RN. In-silico screening of pleconaril and its novel substituted derivatives with neuraminidase of H1N1 influenza strain. BMC Res Notes 2012;5:105
42. Venkatramani L, Johnson E, Kolavi G, et al. Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6. BMC Struct Biol 2012;12:7
43. Mitrasinovic PM. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Biophys Chem 2009;140:35-8
44. Rungrotmongkol T, Frecer V, De-Eknamkul W, et al. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antiviral Res 2009;82:51-8
45. Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78-87
46. Potier M, Mameli L, Belisle M, et al. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-DN- acetylneuraminate) substrate. Anal Biochem 1979;94:287-96
47. Nayak DP, Reichl U. Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus. J Virol Methods 2004;122:9-15
48. Okomo-Adhiambo M, Hurt AC, Gubareva LV. The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Method Mol Biol 2012;865:95-113
49. Buxton RC, Edwards B, Juo RR, et al. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 2000;280:291-300
50. Nguyen HT, Sheu TG, Mishin VP, et al. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010;54:3671-7
51. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003;41:742-50
52. Liu AL, Wang HD, Lee SM, et al. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorg Med Chem 2008;16:7141-7
53. Kongkamnerd J, Milani A, Cattoli G, et al. A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. J Enzyme Inhib Med Chem 2012;27:5-11
54. Liu E-H, Qi L-W, Li P. Structural relationship and binding mechanism of five flavonoids with bovine serum albumin. Molecules 2010;15:9092-103
55. Zhang G, Zhao N, Hu X, Tian J. Interaction of alpinetin with bovine serum albumin: probing the mechanism and binding site by spectroscopic methods. Spectrochimica Acta A 2010;76:410-17
56. Goncalves R, Mateus N, de Freitas V. Biological relevance of the interaction between procyanidines and trypsin: a multitechnique approach. J Agric Food Chem 2010;58:11924-31
57. Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. J Am Med Assoc 2009;301:1066-9
58. von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23
59. Meindl P, Bodo G, Palese P, et al. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-Nacetylneuraminic acid. Virology 1974;58:457-63
60. Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010;50:1252-5
61. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010;362:88-9
62. Macdonald SJ, Cameron R, Demaine DA, et al. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem 2005;48:2964-71
63. Watson KG, Cameron R, Fenton RJ, et al. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorg Med Chem Lett 2004;14:1589-92
64. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009;48:S3-S13
65. Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009;53:186-92
66. TSRL, Inc. Neuraminidase inhibitors. WO2011123856; 2011
67. Gomes P, Santos MI, Trigo MJ, et al. Improved synthesis of amino acid and dipeptide chloromethyl esters using bromochloromethane. ChemInform 2003;34:1683-93
68. Masuda T, Yoshida S, Arai M, et al. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-neu5Ac2en derivatives. Chem Pharm Bull 2003;51:1386-98
69. Sinica, Academia. Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses. WO2011143262; 2011
70. Streicher H, Busse H. Building a successful structural motif into sialylmimetics-cyclohexenephosphonate monoesters as pseudo-sialosides with promising inhibitory properties. Bioorg Med Chem 2006;14:1047-57
71. Schug KA, Lindner W. Noncovalent binding between guanidinium and anionic groups: focus on biological- and synthetic-based arginine/guanidinium interactions with phosphonate and sulfonate residues. Chem Rev 2005;105:67-114
72. Shie J-J, Fang J-M, Lai P-T, et al. A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity. J Am Chem Soc 2011;133:17959-65
73. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997;119:681-90
74. Fuyuno I. Tamiflu side effects come under scrutiny. Nature 2007;446:358-9
75. Kitching A, Roche A, Balasegaram S, et al. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)V, May 2009 - an internet-based crosssectional survey. Eurosurveillance 2009;14:1-4
76. Moscona A. Oseltamivir resistance, disabling our influenza defenses. N Engl J Med 2005;353:2633-6
77. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010;328:1272-5
78. Karpf M, Trussardi R. New, azide-free transformation of epoxides into 1,2-diamino compounds: synthesis of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu). J Org Chem 2001;66:2044-51
79. Hoffmann-La Roche. Process for the preparation of 4,5-diamino shikimic acid derivatives. US20060047002; 2006
80. Hoffmann-La Roche. Process from shikimic acid to oseltamivir phosphate. WO2009037137; 2009
81. Rohloff JC, Kent KM, Postich MJ, et al. Practical total synthesis of the anti-influenza drug GS-4104. J Org Chem 1998;63:4545-50
82. Karpf M, Trussardi R. Efficient access to oseltamivir phosphate (Tamiflu) via the O-trimesylate of shikimic acid ethyl ester. Angew Chem Int Ed Engl 2009;48:5760-2
83. Shibasaki M, Kanai M, Yamatsugu K. Recent development in synthetic strategies for oseltamivir phosphate. Isr J Chem 2011;51:316-28
84. Sinica, Academia. Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity. WO2009029888; 2009
85. Shie J-J, Fang J-M, Wang S-Y, et al. Synthesis of Tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc 2007;129:11892-3
86. Shie JJ, Fang JM, Wong CH. A concise and flexible synthesis of the potent anti-influenza agents Tamiflu and tamiphosphor. Angew Chem Int Ed Engl 2008;47:5788-91
87. Babu YS, Chand P, Kotian PL. Influenza neuraminidase inhibitors as antiviral agents. Annu Rep Med Chem 2006;41:287-97
88. Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expt Rev Anti infect Ther 2012;10:123-43
89. Biocryst Pharm., Inc. Substituted cyclopentane and cyclopentene compound useful as neuraminidase inhibitor. JP2011256196; 2010
90. Mineno T, Miller MJ. Stereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agents. J Org Chem 2003;68:6591-6
91. Peking University Shenzhen GRA. Polysubstituted five-membered ring small molecular compound used as influenza virus neuraminidase inhibitor. CN101486664; 2009
92. Univ. Shandong. Thiazolidine neuraminidase inhibitor and application thereof. CN102146062; 2011
93. Liu Y, Jing F, Xu Y, et al. Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors. Bioorg Med Chem 2011;19:2342-8
94. Nat. Defense Medical CT. 4,5-Diamino- 3-halo-2-hydroxybenzoic acid derivatives and preparations thereof. US2012101157; 2012
95. Singh S, Jedrzejas MJ, Air GM, et al. Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction. J Med Chem 1995;38:3217-25
96. Feng E, Ye D, Li J, et al. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. ChemMedChem 2012;7(9):1527-36
97. Univ. Hunan. Preparation method and medical application of 4-tert-butyl-6- phenyl-2-amino-6H-1,3-thiazine salt. CN101570521; 2009
98. Univ. Hunan. 4-alkyl-6-aryl-5-alkoxy acyl 1,3-thiazine and preparation method and application thereof. CN101805312; 2010
99. Univ. Hunan. 4-alkyl-6-aryl-2-acylamino- 1,3-thiazine-5-formic ether, and preparation method and application thereof. CN101891705; 2010
100. Univ. Hunan. Use of 4-alkyl-6-aryl-5- acetyl-1,3-thiazine for preparing neuraminidase inhibitor. CN102204914; 2011
101. Xia L, Hu A, Cao G, et al. Synthesis and crystal structure of 4-tert-butyl-6-(4- chlorophenyl)-3,6-dihydro-2H-1,3- thiazin-2-iminium chloride. Chinese J Struc Chem 2009;28:33-9
102. Toyama Chemical Co., Ltd. Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination. EP2123276; 2009
103. Univ. of Ryukyus, Bio System Consulting. Influenza virus neuraminidase inhibitor. JP2012077058; 2012
104. Influmedix, Inc. Neuraminidase inhibitors and compositions and methods related thereto. US20110092557; 2011